Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: Involvement of the V1 a receptor

Neuropsychopharmacology

Volumn 38, Issue 11, 2013, Pages 2249-2259

  Ramos, Linnet ^a   Hicks, Callum ^a   Kevin, Richard ^a   Caminer, Alex ^a   Narlawar, Rajeshwar ^b   Kassiou, Michael ^a,b   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adjacent lying; Compound 25; MDMA; Oxytocin; Social interaction; SR49059; Vasopressin; Vasopressin 1A receptor

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; OXYTOCIN; RELCOVAPTAN; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; LOW DRUG DOSE; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HALLUCINOGENS; HORMONE ANTAGONISTS; INDOLES; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXYTOCIN; PYRROLIDINES; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; SOCIAL BEHAVIOR; VASOPRESSINS;

EID: 84884288594     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.125     Document Type: Article

References (76)

1. Ando RD, Benko A, Ferrington L, Kirilly E, Kelly PAT, Bagdy G (2006). Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology 50: 884-896.
2. Andrews J, Newton B, Sahgal A (1983). The effects of vasopressin on positively rewarded responding and on locomotor activity in rats. Neuropeptides 4: 17-29.
3. Appenrodt E, Schnabel R, Schwarzberg H (1998). Vasopressin administration modulates anxiety-related behavior in rats. Physiol Behav 64: 543-547.
4. Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM et al (2012). Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatr; e-pub ahead of print 16 October 2012; doi:10.1016/biopsych.2012.08.025.
5. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E (2008). Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58: 639-650.
6. Bielsky IF, Hu S-B, Ren X, Terwilliger EF, Young LJ (2005). The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 47: 503-513.
7. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ (2004). Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29: 483-493.
8. Bohus B, Ader R, De Wied D (1972). Effects of vasopressin on active and passive avoidance behavior. Horm Behav 3: 191-197.
9. Bowen MT, Carson DS, Spiro A, Arnold JC, McGregor IS (2011). Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. PLoS One 6: e27237.
10. Broadbear JH, Tunstall B, Beringer K (2011). Examining the role of oxytocin in the interoceptive effects of 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstacy") using a drug discrimination paradigm in the rat. Addict Biol 16: 202-214.
11. Brown A, Brown TB, Calabrese A, Ellis D, Puhalo N, Ralph M et al (2010). Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent. Bioorg Med Chem Lett 20: 516-520.
12. Caldwell HK, Lee HJ, Macbeth AH, Young WS 3rd (2008). Vasopressin: behavioral roles of an "original" neuropeptide. Prog Neurobiol 84: 1-24.
13. Capurro A, Reyes-Parada M, Olazabal D, Perrone R, Silveira R, Macadar O (1997). Aggressive behavior and jamming avoidance response in the weakly electric fish Gymnotus carapo: effects of 3, 4-methylenedioxymethamphetamine (MDMA). Comp Biochem Physiol A 118: 831-840.
14. Dantzer R, Koob GF, Le Moal M (1988). Septal vasopressin modulates social memory in male rats. Brain Res 457: 143-147.
15. Debiec J (2005). Peptides of love and fear: vasopressin and oxytocin modulate the integration of information in the amygdala. Bioessays 27: 869-873.
16. Dluzen DE, Muraoka S, Engelmann M, Landgraf R (1998). The effects of infusion of arginine vasopressin, oxytocin, or their antagonists into the olfactory bulb upon social recognition responses in male rats. Peptides 19: 999-1005.
17. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC (2007). Oxytocin improves "mind-reading" in humans. Biol Psychiatr 61: 731-733.
18. Dumont G, Sweep F, van der Steen R, Hermsen R, Donders A, Touw D et al (2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3, 4-methylenedioxymethamphetamine) administration. Soc Neurosci 4: 359-366.
19. Dumont G, Verkes R (2006). A review of acute effects of 3, 4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20: 176-187.
20. Egashira N, Tanoue A, Matsuda T, Koushi E, Harada S, Takano Y et al (2007). Impaired social interaction and reduced anxietyrelated behavior in vasopressin V1a receptor knockout mice. Behav Brain Res 178: 123-127.
21. Engelmann M, Landgraf R (1994). Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav 55: 145-149.
22. Engelmann M, Ludwig M, Landgraf R (2006). Simultaneous monitoring of intracerebral release and behavior: endogenous vasopressin improves social recognition. J Neuroendocrinol 6: 391-395.
23. Ettenberg A, van der Kooy D, Le Moal M, Koob GF, Bloom FE (1983). Can aversive properties of (peripherally-injected) vasopressin account for its putative role in memory? Behav Brain Res 7: 331-350.
24. Fallon J, Shah D, Kicman A, Hutt A, Henry J, Cowan D et al (2002). Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann NY Acad Sci 965: 399-409.
25. Feifel D, MacDonald K, Cobb P, Minassian A (2012). Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res 139: 207-210.
26. Feifel D, Reza T (1999). Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 141: 93-98.
27. Ferguson JN, Aldag JM, Insel TR, Young LJ (2001). Oxytocin in the medial amygdala is essential for social recognition in the mouse. J Neurosci 21: 8278-8285.
28. File SE (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2: 219-238.
29. File SE, Pope J (1974). Social interaction between drugged and undrugged rats. Learn Behav 2: 161-164.
30. Grippo AJ, Trahanas DM, Zimmerman RR 2nd, Porges SW, Carter CS (2009). Oxytocin protects against negative behavioral and autonomic consequences of long-term social isolation. Psychoneuroendocrinology 34: 1542-1553.
31. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS (2009). A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34: 917-923.
32. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M (1998). Low-dose MDMA ("Ecstasy") induces vasopressin secretion. Lancet 351: 1784.
33. Hicks C, Jorgensen W, Brown C, Fardell J, Koehbach J, Gruber CW et al (2012). The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats. J Neuroendocrinol 24: 1012-1029.
34. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L et al (2007). Oxytocin increases retention of social cognition in autism. Biol Psychiatr 61: 498-503.
35. Huber D, Veinante P, Stoop R (2005). Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248.
36. Humphreys AP, Einon DF (1981). Play as a reinforcer for mazelearning in juvenile rats. Anim Behav 29: 259-270.
37. Hunt GE, McGregor IS, Cornish JL, Callaghan PD (2011). MDMAinduced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res Bull 86: 65-73.
38. Insel TR, Winslow JT (1991). Central administration of oxytocin modulates the infant rat's response to social isolation. Eur J Pharmacol 203: 149-152.
39. Insel TR, Winslow JT, Wang Z, Young LJ (1998). Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Adv Exp Med Biol 449: 215-224.
40. Jacob SW, Wood DC (1967). Dimethyl sulfoxide (DMSO) toxicology, pharmacology, and clinical experience. Am J Surg 114: 414-426.
41. Jorgensen H, Riis M, Knigge U, Kjaer A, Warberg J (2003). Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 15: 242-249.
42. Kelly AM, Kingsbury MA, Hoffbuhr K, Schrock SE, Waxman B, Kabelik D et al (2011). Vasotocin neurons and septal V1a-like receptors potently modulate songbird flocking and responses to novelty. Horm Behav 60: 12-21.
43. Koob GF, Le Moal M, Gaffori O, Manning M, Sawyer WH, Rivier J et al (1981). Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats. Regul Pept 2: 153-163.
44. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005). Oxytocin increases trust in humans. Nature 435: 673-676.
45. Latane B, Cappell H, Joy V (1970). Social deprivation, housing density, and gregariousness in rats. J Comp Physiol Psych 70: 221-227.
46. Le Moal M, Dantzer R, Michaud B, Koob G (1987). Centrally injected arginine vasopressin (AVP) facilitates social memory in rats. Neurosci Lett 77: 353-359.
47. Lee HJ, Macbeth AH, Pagani JH, Young WS 3rd (2009). Oxytocin: the great facilitator of life. Prog Neurobiol 88: 127-151.
48. Loyens E, Vermoesen K, Schallier A, Michotte Y, Smolders I (2011). Proconvulsive effects of oxytocin in the generalized pentylenetetrazol mouse model are mediated by vasopressin 1a receptors. Brain Res 1436: 43-50.
49. Lukas M, Neumann ID (2012). Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders. Behav Brain Res; e-pud ahead of print 17 August 2012; doi:10.1016/j.bbr.2012.08.011.
50. Lukas M, Toth I, Reber SO, Slattery DA, Veenema AH, Neumann ID (2011). The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 36: 2159-2168.
51. Maggi M, Malozowski S, Kassis S, Guardabasso V, Rodbard D (1987). Identification and characterization of two classes of receptors for oxytocin and vasopressin in porcine tunica albuginea, epididymis, and vas deferens. Endocrinology 120: 986-994.
52. Maldonado E, Navarro J (2001). MDMA ('Ecstasy') exhibits an anxiogenic-like activity in social encounters between male mice. Pharmacol Res 44: 27-31.
53. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B et al (2012). Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24: 609-628.
54. Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 170: 473-512.
55. McGregor IS, Clemens KJ, Van der Plasse G, Li KM, Hunt GE, Chen F et al (2003). Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28: 1472-1484.
56. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011). The safety and efficacy of ±3, 4-methylenedioxymethamphetamine- assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25: 439-452.
57. Perras B, Droste C, Born J, Fehm HL, Pietrowsky R (1997). Verbal memory after three months of intranasal vasopressin in healthy old humans. Psychoneuroendocrinology 22: 387-396.
58. Pietrowsky R, Struben C, Molle M, Fehm HL, Born J (1996). Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 39: 332-340.
59. Renner MJ, Rosenzweig MR (2004). Social interactions among rats housed in grouped and enriched conditions. Dev Psychobiol 19: 303-313.
60. Rex A, Sondern U, Voigt J, Franck S, Fink H (1996). Strain differences in fear-motivated behavior of rats. Pharmacol Biochem Behav 54: 107-111.
61. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B et al (2006). Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185: 218-225.
62. Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V et al (2011). Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69: 875-882.
63. Schorscher-Petcu A, Sotocinal S, Ciura S, Dupre A, Ritchie J, Sorge RE et al (2010). Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J Neurosci 30: 8274-8284.
64. Simmler LD, Hysek CM, Liechti ME (2011). Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 96: 2844-2850.
65. Slattery D, Neumann I (2010). Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology 58: 56-61.
66. Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A et al (2013). Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol 23: 123-127.
67. Thompson M, Callaghan P, Hunt G, Cornish J, McGregor I (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3, 4 methylenedioxymethamphetamine ('Ecstasy'). Neuroscience 146: 509-514.
68. Thompson M, Hunt G, McGregor I (2009). Neural correlates of MDMA ('Ecstasy')-induced social interaction in rats. Soc Neurosci 4: 60-72.
69. Thompson MR, Callaghan PD, Hunt GE, McGregor IS (2008). Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats. Prog Neuro-Psychopharmacol Biol Psychiatr 32: 1013-1021.
70. Thompson RR, George K, Walton JC, Orr SP, Benson J (2006). Sex-specific influences of vasopressin on human social communication. Proc Natl Acad Sci USA 103: 7889-7894.
71. Thompson RR, Gupta S, Miller K, Mills S, Orr S (2004). The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 29: 35-48.
72. Tobin VA, Hashimoto H, Wacker DW, Takayanagi Y, Langnaese K, Caquineau C et al (2010). An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature 464: 413-417.
73. Tribollet E, Raufaste D, Maffrand JP, Serradeil-Le Gal C (1999). Binding of the non-peptide vasopressin V1A receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology 69: 113-120.
74. Veenema A, Bredewold R, De Vries G (2011). Vasopressin regulates social recognition in juvenile and adult rats of both sexes, but in sex-and age-specific ways. Horm Behav 61: 50-56.
75. Winslow JT (1993). A role for central vasopressin in pair bonding in monogamous prairie voles. Nature 365: 545-547.
76. Witt DM, Winslow JT, Insel TR (1992). Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 43: 855-861.